News | January 14, 2015

Study Demonstrates Favorable Survival Rates for Rectal Cancer Treated With Chemo Agents and Radiation Therapy Prior to Surgery

Study is a secondary endpoint analysis of Radiation Therapy Oncology Group (RTOG) 0247, originally published in 2012, to evaluate long-term survival outcomes and patterns of failure

January 14, 2015 — Locally advanced rectal cancer patients who receive preoperative radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a four-year overall survival rate of 85 percent and 75 percent, respectively, according to a study published in the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).

RTOG 0247 was a randomized, Phase II multicenter trial of patients with locally advanced (T3 and T4) rectal cancer treated with neoadjuvant chemoradiation from March 2004 to February 2007.

The primary endpoint analysis of RTOG 0247 examined the pathologic complete remission (pCR) rates of two concurrent neoadjuvant chemotherapy regimens to determine which regimen should be studied further. The initial results demonstrated that patients who received irinotecan plus capecitabine had lower pCR rates (10 percent compared to those who received oxaliplatin plus capecitabine (21 percent).

The study accrued 146 patients from 59 institutions. All patients received preoperative pelvic radiation therapy of 50.4 Gy over five and a half weeks, with 45 Gy delivered in 25 fractions (1.8 Gy per fraction, five fractions per week for five weeks) and a boost of 5.4 Gy in three fractions. Patients were randomized to two chemotherapy treatment arms concurrent to their radiation therapy.

Patients in arm 1 received concurrent chemotherapy consisting of four doses of irinotecan (50 mg/m2 IV weekly) and capecitabine (1200 mg/m2/d orally Mon. through Fri. during radiation therapy). Patients in arm 2 received concurrent chemotherapy consisting of five doses of oxaliplatin (50 mg/m2 IV weekly) and capecitabine (1600 mg/m2/d orally Mon. through Fri. during radiation therapy).

All patients in each arm had surgery four to six weeks after completion of radiation therapy, and all patients in both arms had postoperative chemotherapy of FOLFOX (Oxaliplatin, leucovorin; 5-fluorouacil (5-FU); and 5-FU infusion) four to six weeks after surgery. Both arms of the study were temporarily closed in January 2005 due to excessive gastrointestinal adverse events. The study reopened in April 2005 with an amended chemotherapy regimen. One hundred four patients, 52 in each arm, were eligible and included in this analysis.

Eligible patients were at least 18-years-old with a median age of 57 years; had clinical stage T3 or T4, potentially resectable adenocarcinoma of the rectum originating ? 12 cm from the anal verge without evidence of distant metastasis; had Zubrod performance of zero to two (the Zubrod performance scale grades patient health status from 0 to 4: a score of 0 means that the patient is “fully active, able to carry on all pre-disease performance without restriction;” and a score of 4 means that the patient is “completely disabled, cannot carry on any self-care, totally confined to a chair or bed”); and had adequate hematologic, renal, cardiac and hepatic function.

Patient evaluations occurred weekly during concurrent chemotherapy and radiation therapy, before surgery and before each cycle of postoperative chemotherapy. Follow-up was conducted every three months for the first two years post-treatment, every six months for the next three years and annually thereafter. The median follow-up for patients in arm 1 was 3.77 years (range 0.19 to 5.23 years), and the median follow-up for patients in arm 2 was 3.97 years (range 0.44 to 5.15 years).

The new study’s analysis of RTOG 0247’s long-term data found that at four-year follow-up, patients in arm 1 (irinotecan plus capecitabine) had an overall survival (OS) rate of 85 percent (44); a disease-free survival (DFS) rate of 68 percent (35), a local-regional failure (LRF) rate of 16 percent (8), a distant failure (DF) rate of 24 percent (12) and a second/new primary failure (SP) rate of 2 percent (1). At four-year follow-up, patients in arm 2 (oxaliplatin plus capecitabine) had an OS rate of 75 percent (39), a DFS rate of 62 percent (32), a LRF rate of 18 percent (9), a DF rate of 30 percent (16) and an SP rate of 6 percent (3). All measures had a 95 percent confidence interval.

“Our new analysis of RTOG 0247 provides us with favorable efficacy results of two preoperative chemotherapy regimens used in conjunction with radiation therapy protocols,” said Neal J. Meropol, M.D., co-author of the study, and the Dr. Lester E. Coleman Jr., professor of Cancer Research and Therapeutics and chief of the Division of Hematology and Oncology at University Hospitals Case Medical Center and Case Western Reserve University in Cleveland. “These favorable long-term survival rates confirm that both of these concurrent chemoradiotherapy regimens followed by surgery can be a highly curative approach for patients with localized rectal cancer, despite the low pCR results we reported in 2012. It is important to find new biomarkers beyond the local remission rate that can help us determine which patients will be cured and who may benefit from more aggressive therapy following chemoradiation.”

For more information: www.astro.org


 

 

Related Content

New Study Evaluates Head CT Examinations and Patient Complexity
News | Neuro Imaging | May 17, 2019
Computed tomography (CT) of the head uses special X-ray equipment to help assess head injuries, dizziness and other...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Managing Architectural Distortion on Mammography Based on MR Enhancement
News | Mammography | May 15, 2019
High negative predictive values (NPV) in mammography architectural distortion (AD) without ultrasonographic (US)...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Icon Launches New Clinical Trial Patient Engagement Platform
Technology | Patient Engagement | May 14, 2019
Icon plc announced the release of its web-based clinical trial patient engagement platform, to provide patients with...
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Radiation Therapy | May 10, 2019
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Screening MRI Detects BI-RADS 3 Breast Cancer in High-risk Patients
News | MRI Breast | May 09, 2019
When appropriate, short-interval follow-up magnetic resonance imaging (MRI) can be used to identify early-stage breast...